Skip to content

Immunovant, Inc. IMVT Interest coverage

Interest coverage at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
24.5×-1.7×
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-5×-1.1×
Summit Therapeutics logo
Summit TherapeuticsSMMT
-26×
TG Therapeutics logo
TG TherapeuticsTGTX
5.4×+3.3×
Roivant Sciences logo
Roivant SciencesROIV
122.5×+104×
IQVIA logo
IQVIAIQV
3.1×-0.4×

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$7.26B+74.2%
Enterprise value$6.35B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Calculated from Immunovant, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s interest coverage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunovant, Inc.'s interest coverage?
Immunovant, Inc. (IMVT) reported interest coverage of -19× in Q1 2026.
How has Immunovant, Inc.'s interest coverage changed year-over-year?
Immunovant, Inc.'s interest coverage decreased by 20.7% year-over-year, from -15.7× to -19×.
What is the long-term trend for Immunovant, Inc.'s interest coverage?
Over 3 years (2023 to 2026), Immunovant, Inc.'s interest coverage has grown at a -10.9% compound annual growth rate (CAGR), from -26.8× to -19×.
What does interest coverage mean?
Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.